Research programme: drug development - Aria Pharmaceuticals
Latest Information Update: 18 May 2021
At a glance
- Originator twoXAR
- Developer Aria Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Idiopathic pulmonary fibrosis; Renal failure; Systemic lupus erythematosus
Most Recent Events
- 04 May 2021 twoXAR Pharmaceuticals is now called Aria Pharmaceuticals